Skip to content

Peter Heerma, EVP, Chief Commercial Officer at Travere Therapeutics, sold TVTX on Sep 17, 2026

Data as of Oct 16

▼ SELL$539K8,282 shares at $65.07Peter Heerma EVP, Chief Commercial OfficerTVTX Travere Therapeutics, Inc.
Watch TVTX
Traded
Sep 17, 2026
Disclosed
Sep 17, 2026
Filed
The same day

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

Peter Heerma, EVP, Chief Commercial Officer at Travere Therapeutics, sold TVTX on Sep 17, 2026TRADEDDISCLOSED
TVTXSimilar stocks (XLV — its sector index fund), rebased to TVTX's price on the disclosure day
TVTX since disclosure
−23.4%
after the sale
Similar stocks (XLV) since disclosure
+4.7%
XLV — its sector index fund

Change in closing price from Sep 17, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

None of our tested rules fired on this trade.

Other trades in the same filing

  1. ▼ SELLPeter Heerma EVP, Chief Commercial OfficerTVTX Travere Therapeutics, Inc.$5Mdisclosed Sep 17 · filed 1 day after the trade
  2. ▼ SELLPeter Heerma EVP, Chief Commercial OfficerTVTX Travere Therapeutics, Inc.$5.9Mdisclosed Sep 17 · filed 1 day after the trade
  3. ▼ SELLPeter Heerma EVP, Chief Commercial OfficerTVTX Travere Therapeutics, Inc.$93.5Kdisclosed Sep 17 · filed 2 days after the trade
  4. ▼ SELLPeter Heerma EVP, Chief Commercial OfficerTVTX Travere Therapeutics, Inc.$1.7Mdisclosed Sep 17 · filed 2 days after the trade
  5. ▼ SELLPeter Heerma EVP, Chief Commercial OfficerTVTX Travere Therapeutics, Inc.$4.5Mdisclosed Sep 17 · filed 2 days after the trade
  6. ▼ SELLPeter Heerma EVP, Chief Commercial OfficerTVTX Travere Therapeutics, Inc.$89.1Kdisclosed Sep 17 · filed 2 days after the trade

See every trade on TVTX →